Quarterly report pursuant to Section 13 or 15(d)

Note 15 - Segments (Tables)

v3.19.1
Note 15 - Segments (Tables)
3 Months Ended
Mar. 31, 2019
Notes Tables  
Schedule of Segment Reporting Information, by Segment [Table Text Block]
T
hree Months Ended March 31, 2019
 
Diagnostics
   
Therapeutics
   
Corporate
   
Total
 
Royalty revenue
  $
3,150
    $
    $
    $
3,150
 
Sublease revenue
   
     
     
94,408
     
94,408
 
Grant and other revenue
   
35,991
     
2,483
     
     
38,474
 
Total revenue
   
39,141
     
2,483
     
94,408
     
136,032
 
Cost of revenue
   
6,126
     
     
     
6,126
 
Research and development expenses
   
740,583
     
     
     
740,583
 
Selling, general and administrative expenses, excluding depreciation and amortization
(1)
   
     
11,714
     
1,774,431
     
1,786,145
 
Depreciation and amortization
(2)
   
     
     
36,779
     
36,779
 
Loss from operations
(3)
   
(707,568
)
   
(9,231
)
   
(1,716,802
)
   
(2,433,601
)
Other income
(4)
   
     
     
8,713
     
8,713
 
Provision for income taxes
   
(256
)
   
(3
)
   
(617
)
   
(876
)
Net loss from continuing operations
   
(707,824
)
   
(9,234
)
   
(1,708,706
)
   
(2,425,764
)
Loss from discontinued operations, net of tax
   
(3,297
)
   
     
     
(3,297
)
Net loss
   
(711,121
)
   
(9,234
)
   
(1,708,706
)
   
(2,429,061
)
Total assets, net of depreciation and amortization:
                               
United States
  $
55,213
    $
2,411
    $
4,891,112
    $
4,948,736
 
International
   
10,422
     
     
602
     
11,024
 
Capital expenditures
   
     
     
     
 
T
hree Months Ended March 31, 2018
 
Diagnostics
   
Therapeutics
   
Corporate
   
Total
 
Royalty revenue
  $
795
    $
    $
    $
795
 
Grant and other revenue
   
232,436
     
43,214
     
     
275,650
 
Total revenue
   
233,231
     
43,214
     
     
276,445
 
Cost of revenue
   
318
     
     
     
318
 
Research and development expenses
   
785,011
     
213,945
     
     
998,956
 
Selling, general and administrative expenses, excluding depreciation and amortization
(1)
   
     
8,607
     
1,729,778
     
1,738,385
 
Depreciation and amortization
(2)
   
     
     
37,987
     
37,987
 
Loss from operations
(3)
   
(552,098
)
   
(179,338
)
   
(1,767,765
)
   
(2,499,201
)
Other expense
(4)
   
     
     
(4,238,761
)
   
(4,238,761
)
Net loss
   
(552,098
)
   
(179,338
)
   
(6,006,526
)
   
(6,737,962
)
Total assets, net of depreciation and amortization:
                               
United States
  $
13,077,979
    $
27,228
    $
5,189,637
    $
18,294,844
 
International
   
26,055
     
     
1,328
     
27,383
 
Capital expenditures